{
  "pmcid": "6500883",
  "sha256": "75a820f72ad456ae4e56c76f5cf849e3140410f5f26448ab515a4084ba28ca44",
  "timestamp_utc": "2025-11-09T22:50:50.448058+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 14.883626318432949,
    "reading_ease": 17.661813159216507,
    "word_count": 181
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Participants": {
        "score": 1,
        "evidence": "This single-center, nonrandomized phase 1 trial enrolled up to 15 adult patients with recurrent glioblastoma"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants underwent biopsy, microdialysis catheter and lumbar drain placement, anti-PD-1 treatment, immune biomarker collection, tumor resection, and anti-PD-1 and anti-LAG-3 treatment until progression."
      },
      "Objective": {
        "score": 1,
        "evidence": "OBJECTIVE: To assess the proportion of patients with increased interferon gamma levels in brain tumor tissue post-nivolumab and evaluate the safety of brain tumor microdialysis for immune response monitoring while assessing the safety of anti-PD-1 and anti-LAG-3 checkpoint inhibition."
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "To assess the proportion of patients with increased interferon gamma levels in brain tumor tissue post-nivolumab"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 1,
        "evidence": "Interferon gamma levels increased in treated patients as measured by microdialysis."
      },
      "Harms": {
        "score": 1,
        "evidence": "Microdialysis was safe, and the combination of anti-LAG-3 and anti-PD-1 had a side effect profile similar to other checkpoint inhibitors."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "TRIAL REGISTRATION: [Trial registration number]."
      },
      "Funding": {
        "score": 0,
        "evidence": "FUNDING: [Source of funding]."
      }
    },
    "total_score": 7,
    "max_score": 25
  }
}